Your institution may have access to this item. Find your institution then sign in to continue.
Title
Is IVIG Treatment Really Better than Natural Recovery in Patients with Guillain-Barré Syndrome?
Abstract
The article discusses the international observational study in which one course of intravenous immunoglobulin (IVIG) did not improve the overall disease course in patients with mild Guillain-Barré syndrome, and IVIG-treated children also did not fare better at six months compared to the natural course. The patients who fared the best were those who had an acute demyelinating syndrome and not an axonal variant. It was an observational study and not a randomized treatment trial.